CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- UPLOAD Other SEC-generated Letter
- 8-K Event Delisting notice
- S-3 Offering Registration Statement
- 10-K Report Annual Report
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 18,000 shares at $0.59 ($10,705)
- 4 Open-market buy Chief Executive Officer bought 37,000 shares at $0.54 ($19,999)
- 8-K Event Shareholder vote results
- 8-K Event Regulation FD disclosure
- 8-K Event Regulation FD disclosure
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy Director bought 10,000 shares at $0.44 ($4,350)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 9,000 shares at an average $0.46 ($4,155)
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 4 Option exercise Director acquired 500,000 shares (option exercise)
- 4 Open-market buy 10% owner bought 1,000 shares at $0.60 ($597)
- 8-K Event Delisting notice
- 8-K Event Regulation FD disclosure
Page 9 of 20 · 398 filings